Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has shared an update.
Lepu Biopharma has secured approval from the Hong Kong Stock Exchange to dis-apply certain biotech-specific listing rules after meeting the market capitalization and revenue thresholds under the exchange’s standard Rule 8.05(3). This reflects the company’s transition from a pre-revenue biotech listing framework to the status of a more mature issuer with at least three years of trading, management continuity, ownership stability, and annual revenue exceeding HKD500 million.
With this change, the “B” marker that identifies it as a Chapter 18A biotech issuer will be removed from Lepu Biopharma’s stock short names from May 11, 2026, and its H shares will continue trading under the unchanged stock code 2157 and new English short name “LEPU BIO.” Existing share certificates, trading arrangements, board lot size, trading currency, and registrar details remain unaffected, signaling a largely symbolic yet strategically important upgrade in the company’s market positioning for investors.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a biotechnology company based in mainland China, listed on the Main Board of the Hong Kong Stock Exchange. The company focuses on developing and commercializing biopharmaceutical products, generating substantial revenue from sales of its commercialized therapies in the Chinese market.
Average Trading Volume: 12,360,946
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.2B
For a thorough assessment of 2157 stock, go to TipRanks’ Stock Analysis page.